11:29 am Applied Genetic Technologies presented data at the ARVO Annual Meeting supporting development of gene-based therapies for achromatopsia; the PR1.7 promoter was found to have comparable efficiency to the PR2.1 promoter in directing – HedgeChatter

11:29 am Applied Genetic Technologies presented data at the ARVO Annual Meeting supporting development of gene-based therapies for achromatopsia; the PR1.7 promoter was found to have comparable efficiency to the PR2.1 promoter in directing

05 May

11:29 am Applied Genetic Technologies presented data at the ARVO Annual Meeting supporting development of gene-based therapies for achromatopsia; the PR1.7 promoter was found to have comparable efficiency to the PR2.1 promoter in directing

Bystocknews AGTC, stock Comments Off

View todays social media effects on AGTC

View the latest stocks trending across Twitter. Click to view dashboard

See who Applied is hiring next, click here to view

Author